Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sandridge Energy Inc.

9.45
+0.16001.72%
Post-market: 9.44-0.0100-0.11%18:42 EDT
Volume:248.91K
Turnover:2.35M
Market Cap:350.52M
PE:5.59
High:9.51
Open:9.34
Low:9.27
Close:9.29
Loading ...

Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis

Business Wire
·
06 Dec 2024

The Zacks Analyst Blog Costco, T-Mobile US, Uber Technologies, SandRidge and Elite Pharmaceuticals

Zacks
·
26 Nov 2024

Top Stock Reports for Costco, T-Mobile US & Uber

Zacks
·
26 Nov 2024

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

GlobeNewswire
·
25 Nov 2024

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

ACCESSWIRE
·
22 Nov 2024

SD Guthrie's New Segments Could Start Contributing From 2026 -- Market Talk

Dow Jones
·
22 Nov 2024

SD Guthrie Likely on Track to Deliver More Disposal Gains in 4Q -- Market Talk

Dow Jones
·
22 Nov 2024

SD Guthrie Should Post Strong 4Q Results -- Market Talk

Dow Jones
·
21 Nov 2024

SD Guthrie Logs Lower Profit in Q3

MT Newswires Live
·
21 Nov 2024

SD Guthrie's 4Q Earnings Outlook Appears Promising -- Market Talk

Dow Jones
·
21 Nov 2024

SD Guthrie's 4Q Earnings Expected to Be Flat -- Market Talk

Dow Jones
·
21 Nov 2024

SD Guthrie Poised for Sequentially Stronger 3Q Earnings -- Market Talk

Dow Jones
·
20 Nov 2024

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

PR Newswire
·
18 Nov 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

GlobeNewswire
·
18 Nov 2024

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

GlobeNewswire
·
16 Nov 2024

Why SandRidge Energy's (NYSE:SD) Shaky Earnings Are Just The Beginning Of Its Problems

Simply Wall St.
·
15 Nov 2024

TPG Telecom Obtains MEF 3.0 SD-WAN Certification for Fortinet SD-WAN Services

MT Newswires Live
·
12 Nov 2024

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

ACCESSWIRE
·
11 Nov 2024

Watch Out: A Huge Number of Altcoins Will Have Massive Token Unlocks in the New Week – Here’s a Day-by-Day, Hour-by-Hour List

CoinMarketCap
·
11 Nov 2024

Q3 2024 SandRidge Energy Inc Earnings Call

Thomson Reuters StreetEvents
·
08 Nov 2024